Cationic Steroid Microbial Compositions and Methods of Use

A method for treating a subject for influenza virus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of cationic steroid antimicrobial (CSA) to treat the subject for the influenza virus infection or pathogenesis.

A method for decreasing susceptibility of a subject to a influenza virus infection or pathogenesis, comprising administering a composition comprising a sufficient amount of cationic steroid antimicrobial (CSA) to decrease susceptibility of the subject to influenza virus infection or pathogenesis.

A method for decreasing or inhibiting influenza virus infection of a cell in vitro or in vivo, comprising administering a composition comprising a sufficient amount of cationic steroid antimicrobial (CSA) to inhibit influenza virus infection of the cell.

A method for providing a subject with protection against an influenza virus infection or pathogenesis, comprising administering a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to provide the subject with protection against the influenza virus infection or pathogenesis.

A method for treating a subject for an influenza virus infection or pathogenesis, comprising administering a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to treat the subject for the influenza virus infection or pathogenesis.

A method for decreasing susceptibility of a subject to an influenza virus infection or pathogenesis, comprising administering a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to decrease susceptibility of the subject to an influenza virus infection or pathogenesis.

A method for reducing, decreasing, inhibiting, ameliorating or preventing onset, severity, duration, progression, frequency or probability of one or more symptoms associated with influenza virus infection or pathogenesis in a subject, comprising administering a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to decrease, inhibit, ameliorate or prevent onset, severity, duration, progression, frequency or probability of one or more symptoms associated with influenza virus infection or pathogenesis in the subject.

A method for identifying a candidate agent for treating a subject for an influenza virus infection or pathogenesis, comprising:

• a) providing a test agent, said test agent comprising a cationic steroid antimicrobial (CSA);
• b) contacting said test agent with influenza virus and ascertaining whether the test agent inhibits influenza virus infection or pathogenesis, wherein a test agent identified as inhibiting influenza virus infection or pathogenesis is a candidate agent for treating a subject for influenza virus infection or pathogenesis.

A method for identifying a candidate agent for decreasing susceptibility of a subject to an influenza virus infection or pathogenesis, comprising:

• a) providing a test agent, said test agent comprising a cationic steroid antimicrobial (CSA);
• b) contacting said test agent with influenza virus and ascertaining whether the test agent inhibits influenza virus infection or pathogenesis, wherein a test agent identified as inhibiting influenza virus infection or pathogenesis is a candidate agent for decreasing susceptibility of a subject to an influenza virus infection or pathogenesis.

A method for identifying a candidate agent for decreasing, inhibiting, ameliorating or preventing onset, severity, duration, progression, frequency or probability of one or more symptoms associated with influenza virus infection or pathogenesis, comprising:

• a) providing a test agent, said test agent comprising a cationic steroid antimicrobial (CSA);
• b) administering said test agent to a subject infected with or exposed to influenza virus and ascertaining whether the test agent decreases, inhibits, ameliorates or prevents onset, severity, duration, progression, frequency or probability of one or more symptoms associated with influenza virus infection or pathogenesis, wherein a test agent identified is a candidate agent for decreasing, inhibiting, ameliorating or preventing onset, severity, duration, progression, frequency or probability of one or more symptoms associated with influenza virus infection or pathogenesis.